GO:0102673 fatty aldehyde dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0102673 describes fatty aldehyde dehydrogenase (NAD+) activity, the catalysis of a fatty aldehyde + H2O + NAD+ to a fatty acid + 2 H+ + NADH.
• The enzyme is a microsomal NAD+-dependent oxidoreductase that is best known as the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase.
• Deficient activity of this enzyme is the biochemical hallmark of Sjogren-Larsson syndrome, an inherited neurocutaneous disorder.
• Recombinant human fatty aldehyde dehydrogenase has been purified and characterized, enabling direct study of its catalytic and inhibitory properties.
• Bacterial homologs from Marinobacter and Acinetobacter spp. provide structural insights into the aldehyde binding pocket of fatty aldehyde dehydrogenases.
• CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of fatty aldehyde dehydrogenase (NAD+) activity in disease and metabolism.
Description
GO:0102673, fatty aldehyde dehydrogenase (NAD+) activity, is a molecular function term describing the NAD+-dependent oxidation of a fatty aldehyde to the corresponding fatty acid, with concomitant reduction of NAD+ to NADH. This activity is classically measured as the fatty aldehyde dehydrogenase component of the fatty alcohol:NAD+ oxidoreductase complex, which converts fatty alcohol to fatty acid through a fatty aldehyde intermediate. The reaction is central to lipid metabolism because it removes reactive fatty aldehydes and generates fatty acids for membrane and signaling pathways. The term matters to researchers because loss of this activity is directly linked to human disease. Cultured fibroblasts from patients with Sjogren-Larsson syndrome show deficient fatty aldehyde dehydrogenase activity, establishing the enzyme as the causal biochemical defect in that disorder. Carrier detection studies have further used this activity to identify heterozygous individuals. Beyond disease genetics, the enzyme is a target for structural and mechanistic studies of aldehyde oxidation, cofactor specificity and substrate recognition. Because fatty aldehydes are reactive and potentially toxic, the NAD+-dependent oxidation catalyzed by this enzyme is also relevant to cellular protection and lipid homeostasis. Understanding GO:0102673 therefore connects enzymology, inherited metabolic disease and modern CRISPR-based functional genomics.
fatty aldehyde dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0102673 |
|---|---|
| GO term | fatty aldehyde dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | fatty aldehyde dehydrogenase activity |
| Definition | Catalysis of the reaction: a fatty aldehyde + H2O + NAD+ = a fatty acid + 2 H+ + NADH. |
| Major function | NAD+-dependent oxidation of fatty aldehydes to fatty acids |
| Cofactor | NAD+ (nicotinamide adenine dinucleotide) |
| Subcellular context | Microsomal membranes |
| Disease link | Sjogren-Larsson syndrome |
What Is GO:0102673?
GO:0102673 is defined as the catalysis of the reaction: a fatty aldehyde + H2O + NAD+ = a fatty acid + 2 H+ + NADH. In other words, it is the NAD+-dependent oxidation of a fatty aldehyde to a fatty acid, releasing protons and generating NADH. The activity is typically associated with microsomal membranes and is the fatty aldehyde dehydrogenase component of the fatty alcohol:NAD+ oxidoreductase system.
Why Is fatty aldehyde dehydrogenase (NAD+) activity Important in Cell Biology?
GO:0102673 is important because it defines the enzymatic step that clears fatty aldehydes and produces fatty acids, and because inherited deficiency of this activity causes Sjogren-Larsson syndrome, a severe neurocutaneous disorder. The enzyme is also a model for understanding NAD+-dependent aldehyde oxidation, substrate specificity and the structural basis of fatty aldehyde recognition.
• Provides the biochemical definition of the fatty aldehyde dehydrogenase step in fatty alcohol oxidation.
• Deficient activity is the diagnostic hallmark of Sjogren-Larsson syndrome.
• Enables carrier detection and genetic counseling in affected families.
• Supports gene therapy development, as AAV vectors can restore fatty aldehyde dehydrogenase deficiency.
• Offers a tractable target for structural studies of the aldehyde binding pocket.
• Helps explain the toxicity of accumulated fatty aldehydes in metabolic disease.
• Connects lipid metabolism to membrane homeostasis and signaling.
• Provides a functional readout for CRISPR knockout and knock-in models.
• Guides inhibitor and activator studies using recombinant human enzyme.
• Links bacterial and human enzyme homologs for comparative enzymology.
Molecular Mechanism of fatty aldehyde dehydrogenase (NAD+) activity
Substrate binding and aldehyde recognition
In simple terms: The enzyme first grabs a fatty aldehyde and holds it in place.
Fatty aldehyde dehydrogenase (NAD+) activity acts on a fatty aldehyde substrate, positioning the aldehyde group for oxidation. Structural studies of bacterial fatty aldehyde dehydrogenases from Marinobacter and Acinetobacter spp. have provided insights into the aldehyde binding pocket, showing how the enzyme accommodates the aldehyde moiety. The human enzyme is microsomal and has been purified and biochemically characterized, confirming its preference for fatty aldehyde substrates.
NAD+ binding and hydride transfer
In simple terms: NAD+ accepts electrons from the aldehyde, turning into NADH.
The reaction requires NAD+ as the electron acceptor. Catalysis proceeds through oxidation of the fatty aldehyde to a fatty acid, with reduction of NAD+ to NADH and release of two protons. The NAD+-specific nature of this activity distinguishes it from NADP+-specific fatty aldehyde dehydrogenases, such as the Vibrio harveyi enzyme in which cysteine 289 is involved in catalytic activity.
Catalytic residues and mechanism
In simple terms: Specific amino acids in the enzyme do the chemical work.
Characterization of recombinant human fatty aldehyde dehydrogenase has provided implications for Sjogren-Larsson syndrome and for the catalytic mechanism of the human enzyme. Comparative studies of NADP+-specific fatty aldehyde dehydrogenase from Vibrio harveyi identified cysteine 289 as important for catalytic activity, highlighting the role of active-site residues in aldehyde oxidation. These findings inform models of the human NAD+-dependent enzyme.
Product release and microsomal context
In simple terms: After the reaction, the fatty acid and NADH are released.
The products of the reaction are a fatty acid, two protons and NADH. Human liver fatty aldehyde dehydrogenase is microsomally localized, and its purification and biochemical characterization confirmed this membrane association. This localization places the activity in the endoplasmic reticulum membrane, where it participates in lipid metabolic pathways.
Role in the fatty alcohol:NAD+ oxidoreductase system
In simple terms: It is one part of a two-step enzyme system that converts fatty alcohol to fatty acid.
Fatty aldehyde dehydrogenase (NAD+) activity is the second component of the fatty alcohol:NAD+ oxidoreductase system, which oxidizes fatty alcohol to fatty aldehyde and then to fatty acid. In Sjogren-Larsson syndrome, deficient activity of this component was demonstrated in cultured fibroblasts, linking the enzyme directly to the disease.
Key Genes Involved in GO:0102673 fatty aldehyde dehydrogenase (NAD+) activity
The genes and proteins below are directly implicated in fatty aldehyde dehydrogenase (NAD+) activity, its regulation or its disease associations.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH3A2 | Encodes the human fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase | Causally linked to Sjogren-Larsson syndrome; target for knockout and knock-in models |
| ALDH3A2 (C289) | Active-site cysteine residue implicated in catalysis in related enzymes | Point-mutation studies of catalytic mechanism |
| ALDH3A2 (NAD+ binding) | NAD+ cofactor binding and hydride transfer | Mutational analysis of cofactor specificity |
| Marinobacter spp. FALDH | Bacterial fatty aldehyde dehydrogenase homolog | Structural insights into aldehyde binding pocket |
| Acinetobacter spp. FALDH | Bacterial fatty aldehyde dehydrogenase homolog | Comparative enzymology and substrate specificity |
| Vibrio harveyi FALDH | NADP+-specific fatty aldehyde dehydrogenase | Model for active-site cysteine function |
| ALDH3A2 (microsomal form) | Microsomal localization of human liver enzyme | Membrane association and purification studies |
| ALDH3A2 (recombinant) | Recombinant human enzyme for biochemical assays | Inhibitor and mechanism studies |
| ALDH3A2 (carrier variants) | Heterozygous carrier state with reduced activity | Carrier detection and genetic counseling |
| ALDH3A2 (AAV target) | Restoration of enzyme activity by gene transfer | Gene therapy development for Sjogren-Larsson syndrome |
| Fatty alcohol:NAD+ oxidoreductase complex | Multicomponent system converting fatty alcohol to fatty acid | Pathway-level studies of lipid metabolism |
| NAD+ | Essential cofactor for the oxidation reaction | Cofactor dependence and redox balance |
| Fatty aldehyde substrates | Substrates oxidized to fatty acids | Substrate specificity and enzyme kinetics |
| Fatty acid products | Products of the reaction | Lipid profiling and metabolic flux |
| Sjogren-Larsson syndrome-associated variants | Disease-causing alleles of ALDH3A2 | Genotype-phenotype correlation |
| AAV vector components | Delivery tools for gene replacement | Preclinical gene therapy |
| Fibroblast models | Patient-derived cells with deficient activity | Diagnostic and mechanistic studies |
| Recombinant expression systems | Production of active enzyme for assays | Biochemical characterization |
How Is fatty aldehyde dehydrogenase (NAD+) activity Regulated?
Fatty aldehyde dehydrogenase (NAD+) activity is regulated at the level of enzyme abundance and cofactor availability. The enzyme is microsomally localized, and its activity depends on NAD+ as the electron acceptor. In disease, loss-of-function variants in ALDH3A2 reduce or abolish activity, as demonstrated in cultured fibroblasts from Sjogren-Larsson syndrome patients. Carrier individuals show intermediate activity levels, indicating a gene-dosage effect. Recombinant human enzyme studies have explored how inhibitors and substrate analogs affect catalytic activity, providing insight into potential regulatory mechanisms. Bacterial homolog studies have revealed active-site features that influence catalysis.
fatty aldehyde dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH3A2 | Sjogren-Larsson syndrome | Patient fibroblasts and CRISPR knockout cell lines |
| ALDH3A2 | Carrier state with reduced activity | Heterozygous knock-in or point-mutation models |
| ALDH3A2 | Gene therapy target | AAV-mediated overexpression in deficient cells |
| ALDH3A2 | Lipid metabolism and aldehyde clearance | Knockout and overexpression models |
| Bacterial FALDH homologs | Comparative enzymology | Recombinant expression and structural studies |
Sjogren-Larsson syndrome
Sjogren-Larsson syndrome is an inherited neurocutaneous disorder caused by deficient fatty aldehyde dehydrogenase (NAD+) activity. Cultured fibroblasts from patients show markedly reduced activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase, establishing the biochemical basis of the disease. The condition is characterized by ichthyosis, spasticity and intellectual disability, and the enzyme defect is central to its pathogenesis.
Carrier state and genetic counseling
Heterozygous carriers of ALDH3A2 variants can be detected by measuring fatty aldehyde dehydrogenase activity, which is reduced relative to unaffected individuals. This has practical implications for genetic counseling in families affected by Sjogren-Larsson syndrome.
Gene therapy approaches
Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase deficiency in cellular models, supporting gene therapy as a potential treatment strategy for Sjogren-Larsson syndrome. This work highlights the therapeutic relevance of restoring GO:0102673 activity.
Lipid metabolism and aldehyde toxicity
Because the enzyme clears fatty aldehydes, its deficiency can lead to accumulation of reactive aldehydes and altered lipid metabolism. The microsomal localization of the human enzyme places it at a key node in lipid handling.
From fatty aldehyde dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH3A2 abolish fatty aldehyde dehydrogenase activity? | CRISPR knockout cell line |
| Which residues are required for catalysis? | Point-mutation knock-in of active-site residues |
| Can wild-type enzyme rescue the deficiency? | Knock-in or overexpression of ALDH3A2 |
| How does the enzyme localize in cells? | Tagged knock-in with fluorescent or epitope tag |
| Can gene therapy restore activity? | AAV-mediated overexpression in patient cells |
| What is the substrate specificity? | Recombinant enzyme overexpression and biochemical assays |
How to Study the fatty aldehyde dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | NADH production or fatty acid formation | Diagnosis and biochemical characterization |
| Recombinant expression | Purified enzyme for kinetics | Mechanism and inhibitor studies |
| Structural biology | Aldehyde binding pocket architecture | Substrate recognition |
| Site-directed mutagenesis | Role of active-site residues | Catalytic mechanism |
| AAV transduction | Restoration of enzyme activity | Gene therapy development |
| Carrier detection assay | Intermediate activity levels | Genetic counseling |
| Fibroblast culture | Endogenous enzyme activity | Disease modeling |
| Comparative enzymology | Cofactor specificity | Evolutionary and mechanistic insights |
Enzyme activity assays
Fatty aldehyde dehydrogenase (NAD+) activity is typically measured by monitoring NADH production or fatty acid formation using fatty aldehyde substrates. This approach was used to demonstrate deficient activity in Sjogren-Larsson syndrome fibroblasts and to characterize the purified human enzyme.
Recombinant protein production and characterization
Recombinant human fatty aldehyde dehydrogenase has been expressed and characterized to study its catalytic properties and inhibition, providing implications for Sjogren-Larsson syndrome. Bacterial homologs have also been produced for structural and biochemical studies.
Structural biology
Structural insights into the aldehyde binding pocket of fatty aldehyde dehydrogenases from Marinobacter and Acinetobacter spp. have been obtained, informing models of substrate recognition. Comparative analysis with NADP+-specific enzymes highlights active-site differences.
Cell-based and gene therapy models
Patient-derived fibroblasts and AAV-transduced cells are used to study deficiency and restoration of activity. These models are valuable for testing therapeutic strategies.
How CRISPR Can Be Used to Study GO:0102673 fatty aldehyde dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of ALDH3A2 can eliminate fatty aldehyde dehydrogenase (NAD+) activity, creating cellular models that mimic Sjogren-Larsson syndrome. These models are useful for studying lipid metabolism and aldehyde toxicity.
Point Mutation
Point mutations in ALDH3A2 can be introduced to test the role of specific residues, such as active-site cysteines implicated in related enzymes. This helps dissect catalytic mechanism and genotype-phenotype relationships.
Knock-in
Knock-in of wild-type or tagged ALDH3A2 allows restoration of activity and tracking of the enzyme in cells. Tagged knock-in models are valuable for localization studies.
Overexpression
Overexpression of ALDH3A2 can rescue deficiency and provide material for biochemical assays. This is particularly relevant for gene therapy development.
How EDITGENE Supports fatty aldehyde dehydrogenase (NAD+) activity Research
Researchers studying fatty aldehyde dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in the observed phenotype, and CRISPR-based models provide a direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for fatty aldehyde dehydrogenase (NAD+) activity research.
Frequently Asked Questions About fatty aldehyde dehydrogenase (NAD+) activity
What is fatty aldehyde dehydrogenase (NAD+) activity?
It is the NAD+-dependent oxidation of a fatty aldehyde to a fatty acid, defined by GO:0102673.
What genes are involved in fatty aldehyde dehydrogenase (NAD+) activity?
ALDH3A2 encodes the human enzyme, and bacterial homologs are found in Marinobacter and Acinetobacter spp..
What disease is linked to fatty aldehyde dehydrogenase deficiency?
Sjogren-Larsson syndrome is caused by deficient activity of this enzyme.
How is fatty aldehyde dehydrogenase activity measured?
It is measured by monitoring NADH production or fatty acid formation using fatty aldehyde substrates.
What is the reaction catalyzed by GO:0102673?
A fatty aldehyde + H2O + NAD+ = a fatty acid + 2 H+ + NADH.
Is fatty aldehyde dehydrogenase microsomal?
Yes, the human liver enzyme is microsomally localized.
Can gene therapy restore fatty aldehyde dehydrogenase activity?
AAV vectors can restore deficiency in cellular models.
What are the research models for this activity?
Knockout, point-mutation, knock-in and overexpression cell models are used.
What is the role of NAD+ in this reaction?
NAD+ is the electron acceptor, reduced to NADH during fatty aldehyde oxidation.
How can carriers of Sjogren-Larsson syndrome be detected?
By measuring reduced fatty aldehyde dehydrogenase activity in cultured cells.
Conclusion
GO:0102673, fatty aldehyde dehydrogenase (NAD+) activity, defines a key lipid metabolic reaction with direct links to Sjogren-Larsson syndrome and aldehyde clearance. The enzyme has been purified, characterized and structurally informed by bacterial homologs, providing a solid foundation for mechanistic studies. CRISPR-based knockout, point-mutation, knock-in and overexpression models now enable causal testing of this activity in disease and metabolism.
References
- 1. Rizzo WB et al.. 1991. Sjögren-Larsson syndrome. Deficient activity of the fatty aldehyde dehydrogenase component of fatty alcohol:NAD+ oxidoreductase in cultured fibroblasts.. J Clin Invest 88(5):1643-8 PMID: 1939650
- 2. Rizzo WB. 1993. Sjögren-Larsson syndrome.. Semin Dermatol 12(3):210-8 PMID: 8217559
- 3. Kelson TL et al.. 1997. Human liver fatty aldehyde dehydrogenase: microsomal localization, purification, and biochemical characterization.. Biochim Biophys Acta 1335(1-2):99-110 PMID: 9133646
- 4. Bertram JH et al.. 2017. Five Fatty Aldehyde Dehydrogenase Enzymes from Marinobacter and Acinetobacter spp. and Structural Insights into the Aldehyde Binding Pocket.. Appl Environ Microbiol 83(12) PMID: 28389542
- 5. Lloyd MD et al.. 2007. Characterisation of recombinant human fatty aldehyde dehydrogenase: implications for Sjögren-Larsson syndrome.. J Enzyme Inhib Med Chem 22(5):584-90 PMID: 18035827
- 6. Vedadi M et al.. 1995. Involvement of cysteine 289 in the catalytic activity of an NADP(+)-specific fatty aldehyde dehydrogenase from Vibrio harveyi.. Biochemistry 34(51):16725-32 PMID: 8527447
- 7. Kelson TL et al.. 1992. Carrier detection for Sjögren-Larsson syndrome.. J Inherit Metab Dis 15(1):105-11 PMID: 1583866
- 8. Haug S et al.. 2005. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implications for gene therapy in Sjogren-Larsson syndrome.. Arch Dermatol Res 296(12):568-72 PMID: 15834613
